CN113939315A - 治疗黑色素瘤的联用药物组合物 - Google Patents

治疗黑色素瘤的联用药物组合物 Download PDF

Info

Publication number
CN113939315A
CN113939315A CN202080038348.3A CN202080038348A CN113939315A CN 113939315 A CN113939315 A CN 113939315A CN 202080038348 A CN202080038348 A CN 202080038348A CN 113939315 A CN113939315 A CN 113939315A
Authority
CN
China
Prior art keywords
seq
antibody
pharmaceutical composition
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080038348.3A
Other languages
English (en)
Other versions
CN113939315B (zh
Inventor
杨朝强
李琳
赵颖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Nanjing Shunxin Pharmaceutical Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Nanjing Shunxin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Nanjing Shunxin Pharmaceutical Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN113939315A publication Critical patent/CN113939315A/zh
Application granted granted Critical
Publication of CN113939315B publication Critical patent/CN113939315B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本申请属于生物医药领域,涉及治疗黑色素瘤的联用药物组合物,其包括抗PD‑L1抗体和安罗替尼,其具有良好的抗黑色素瘤活性。

Description

PCT国内申请,说明书已公开。

Claims (20)

  1. PCT国内申请,权利要求书已公开。
CN202080038348.3A 2019-05-30 2020-05-29 治疗黑色素瘤的联用药物组合物 Active CN113939315B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910462927 2019-05-30
CN201910462927X 2019-05-30
PCT/CN2020/093351 WO2020239085A1 (zh) 2019-05-30 2020-05-29 治疗黑色素瘤的联用药物组合物

Publications (2)

Publication Number Publication Date
CN113939315A true CN113939315A (zh) 2022-01-14
CN113939315B CN113939315B (zh) 2024-04-02

Family

ID=73553503

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080038348.3A Active CN113939315B (zh) 2019-05-30 2020-05-29 治疗黑色素瘤的联用药物组合物

Country Status (2)

Country Link
CN (1) CN113939315B (zh)
WO (1) WO2020239085A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220160700A1 (en) * 2018-07-18 2022-05-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Therapeutic combination of quinoline derivative and antibody
US20230285554A1 (en) * 2020-08-13 2023-09-14 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combined medication for treating soft tissue sarcoma
EP4374875A1 (en) * 2021-07-22 2024-05-29 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combination drug for treatment of gastric carcinoma and/or esophagogastric junction cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001463A (zh) * 2014-08-05 2017-08-01 中美冠科生物技术(太仓)有限公司 抗pd‑l1抗体
CN107771078A (zh) * 2015-05-04 2018-03-06 爱德程医药有限公司 用于制备抗癌剂1‑((4‑(4‑氟‑2‑甲基‑1h‑吲哚‑5‑基氧基)‑6‑甲氧基喹啉‑7‑基氧基)甲基)环丙胺、其结晶形式和其盐的方法
CN108601831A (zh) * 2016-10-10 2018-09-28 苏州盛迪亚生物医药有限公司 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途
CN113518621A (zh) * 2019-03-07 2021-10-19 南京爱德程医药科技有限公司 按顺序使用卡奎替尼(安罗替尼)和标准化学疗法或免疫疗法的组合以治疗癌症

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001463A (zh) * 2014-08-05 2017-08-01 中美冠科生物技术(太仓)有限公司 抗pd‑l1抗体
CN107771078A (zh) * 2015-05-04 2018-03-06 爱德程医药有限公司 用于制备抗癌剂1‑((4‑(4‑氟‑2‑甲基‑1h‑吲哚‑5‑基氧基)‑6‑甲氧基喹啉‑7‑基氧基)甲基)环丙胺、其结晶形式和其盐的方法
CN108601831A (zh) * 2016-10-10 2018-09-28 苏州盛迪亚生物医药有限公司 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途
CN113518621A (zh) * 2019-03-07 2021-10-19 南京爱德程医药科技有限公司 按顺序使用卡奎替尼(安罗替尼)和标准化学疗法或免疫疗法的组合以治疗癌症

Also Published As

Publication number Publication date
CN113939315B (zh) 2024-04-02
WO2020239085A1 (zh) 2020-12-03

Similar Documents

Publication Publication Date Title
CN113347996B (zh) 治疗肿瘤的联用药物组合物
CN113613674A (zh) 治疗小细胞肺癌的联用药物组合物
CN113939315B (zh) 治疗黑色素瘤的联用药物组合物
WO2020249018A1 (zh) 治疗驱动基因阳性肺癌的联用药物组合物
CN113018429A (zh) 治疗卵巢癌的药物组合
CN112168961A (zh) 治疗结直肠癌的联用药物组合物
CN116437957A (zh) 用于治疗肺癌的抗PD-L1抗体和c-Met激酶抑制剂的联用药物组合物
WO2021244551A1 (zh) c-Met激酶抑制剂和抗PD-L1抗体的联用药物组合物
WO2021219138A1 (zh) 用于治疗肾癌的联用药物
CN113117072A (zh) 喹啉衍生物与pd-1单抗的药物组合
CN114667159B (zh) 喹啉衍生物与pd-1单抗的药物组合
WO2023174408A1 (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
WO2023198060A1 (zh) 蛋白酶体抑制剂与抗pd-1抗体的药物组合
WO2023174278A1 (zh) 抗tim-3抗体与去甲基化药物的药物组合
CN118267469A (zh) 治疗驱动基因阳性肺癌的联用药物组合物
CN118267468A (zh) 治疗肿瘤的联用药物组合物
WO2023217268A1 (zh) 抗tim-3抗体与抗pd-1抗体的药物组合
CN117085123A (zh) 抗PD-L1抗体和c-Met激酶抑制剂的药物组合
CN117085124A (zh) 一种包含抗PD-L1抗体和c-Met激酶抑制剂的药物组合
CN118176017A (zh) 治疗肿瘤的联用药物
WO2023232100A1 (zh) 用于治疗子宫恶性肿瘤的药物组合
CN116209443A (zh) 治疗小细胞肺癌的药物组合
CN117815387A (zh) Cdk4/6抑制剂和抗pd-l1抗体的联用药物组合物
US20230285554A1 (en) Combined medication for treating soft tissue sarcoma
CN116036265A (zh) 用于癌症的联用药物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant